Unveiling the Surge: MASLD Prevalence Trends in India Since 1990

Recent research publications have shed light on a silent epidemic sweeping through India: the dramatic rise in metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD). A landmark study utilizing Global Burden of Disease (GBD) data reveals that India's age-standardized MASLD prevalence rate climbed from 10,191 per 100,000 population in 1990 to 12,555 per 100,000 in 2023, marking a 23.19% increase. This surge positions India among the top countries grappling with this condition, driven primarily by escalating rates of type 2 diabetes and obesity. Researchers from institutions like the Indian Institute of Public Health-Gandhinagar (IIPH-Gandhinagar) have contributed to global analyses highlighting how metabolic risk factors, particularly high fasting plasma glucose and elevated body mass index (BMI), are accelerating this trend in South Asia's most populous nation.

The shift in terminology from NAFLD to MASLD emphasizes the metabolic underpinnings, encompassing fat accumulation in the liver (steatosis) linked to insulin resistance, irrespective of alcohol consumption. In India, where diabetes affects over 100 million adults and obesity rates have tripled since the 1990s, MASLD has transitioned from a niche concern to a public health crisis. Community-based studies estimate pooled prevalence at 38.6% among adults, with urban areas reporting up to 60% in high-risk groups. This organic progression prompts a deeper dive into the data from key Indian-led research.

Decoding MASLD: Pathophysiology and Risk Stratification

MASLD develops when excess fat exceeds 5% of liver cells, often without symptoms in early stages. The process begins with insulin resistance impairing fat metabolism, leading to triglyceride buildup in hepatocytes. Step-by-step, this triggers inflammation (steatohepatitis), fibrosis, cirrhosis, and hepatocellular carcinoma if unchecked. In the Indian context, genetic predispositions like PNPLA3 gene variants, combined with environmental shifts—high-carb diets rich in refined sugars and saturated fats, sedentary urban lifestyles—exacerbate vulnerability.

Non-invasive tools like vibration-controlled transient elastography (FibroScan) measure controlled attenuation parameter (CAP) for steatosis and liver stiffness measurement (LSM) for fibrosis. Indian studies validate these: CAP ≥238 dB/m indicates MASLD, LSM ≥7 kPa suggests significant fibrosis. Lean MASLD, affecting 15% of cases despite normal BMI, underscores central obesity's role, measured via waist circumference (>90 cm men, >80 cm women), prevalent in South Asians due to 'thin-fat' phenotype.

Global Burden Study Insights: India's Trajectory from 1990 to 2023

The GBD 2021 study, published in Metabolism, analyzed MASLD across 204 countries, revealing a global prevalence jump of nearly 29% (143% in crude cases to 1.3 billion). India's ascent mirrors this, with high blood sugar contributing 2.2 disability-adjusted life years (DALYs) per 100,000 globally—the top driver. Nationally, age-standardized DALYs dipped 11.3% (23.8 to 21.1 per 100,000), hinting at better management, yet absolute cases soar with population growth.

Authors including Anoop Misra from Fortis C-DOC Hospital highlight India's vulnerability: highest absolute burden alongside China and USA. Projections warn of 1.8 billion global cases by 2050, with India facing amplified risks from demographic shifts. Projections to 2036 from related GBD analyses predict sustained rises unless interventions target metabolic clusters.

The MAP Study: Landmark Data from 13,750 Indians

Led by Viswanathan Mohan at Madras Diabetes Research Foundation (MDRF), an ICMR Centre of Excellence, the Mapping Across Populations (MAP) study screened 13,750 adults across 105 clinics in 23 states (May 2023–Feb 2024). Findings: 68.2% MASLD prevalence, 33.7% fibrosis, 12.2% cirrhosis. North zone topped at 73.3%, central 69.4%; states like Uttarakhand (80%) and Punjab (78.6%) led. Full MAP study details reveal no age correlation, urging universal screening.

Collaborators from Lilavati Hospital Mumbai, Ananda Medicare Delhi, and others underscore multisite rigor. Fibrosis highest in north/central zones (P<0.001), linking to dietary fats and genetics. This real-world data from endocrine clinics highlights diabetes overlap: prior estimates peg MASLD at 55–75% in T2D patients.

Regional Disparities: North vs South India Contrasts

MAP data exposes stark zonal variances: Jammu & Kashmir severe steatosis 50.3%, Kerala cirrhosis 20%. North's high-fat diets contrast south's carb-heavy rice/coconut oil intake, both fueling insulin resistance. A PGIMER Chandigarh review notes 141% case rise, 169% deaths 1990–2021, highest DALYs in 55–69 age group.

• North: 73.3% MASLD, genetics + saturated fats.
• South: 67.3%, refined carbs + urban sedentariness.
• West: 60.9%, mixed metabolic risks.
• East/Northeast: Lower but rising with urbanization.

Meta-analyses from AIIMS Delhi and SGPGIMS Lucknow confirm urban 40%, rural 29.2%; children 35.4%, obese kids 63.4%.

Photo by Just random Captures on Unsplash

Diabetes and Obesity: The Twin Engines of the Epidemic

India, diabetes capital (101 million cases), sees MASLD in 60–85% T2D patients. Insulin resistance links high glucose to hepatic fat via de novo lipogenesis. Obesity triples risk; BMI >25 (prevalent in 30% adults) correlates with severity, though lean MASLD (15%) via visceral fat persists. ICMR-INDIAB study ties metabolic syndrome (30% prevalence) directly.

Trends: Diabetes deaths up since 1990; obesity from 5% (1990s) to 20%+. Urban desk jobs, processed foods (sugary drinks up 300%) compound. Step-by-step: Hyperinsulinemia → fat influx → oxidative stress → NASH → fibrosis.

Complications, Burden, and Economic Implications

MASLD progresses silently: 20–30% to NASH, 10–20% fibrosis/cirrhosis, 2–5% HCC. India: 141% cases, 169% deaths 1990–2021; DALYs peak midlife. Economic toll: OOP costs rival heart failure. GBD notes stable DALYs but rising crude burden from population/demographics.AIIMS meta-analysis warns of underdiagnosis.

Cultural context: Stigma delays care; 'fatty liver' dismissed as lifestyle, ignoring genetics/diet.

Screening Protocols and Diagnostic Advances from Indian Research

FibroScan gold standard per MDRF/PGIMER. FIB-4, NAFLD Fibrosis Score for risk-stratify. Guidelines: Screen T2D/obese via ultrasound + ALT. MAP validates CAP/LSM regionally. AIIMS studies push community FibroScan rollout.

• Step 1: Anthropometrics (WC, BMI).
• Step 2: Labs (ALT/AST, GGT, lipids, HbA1c).
• Step 3: Imaging (USG/FibroScan).
• Step 4: Advanced (MRE, biopsy if needed).

Management Strategies: Evidence from Indian Trials

Lifestyle first: 7–10% weight loss reverses 80% cases. Saroglitazar (Indian-developed) reduces fat 10–15% in trials. Pioglitazone/GLP-1 agonists for diabetics. PGIMER: Multidisciplinary—diet (Mediterranean-Indian hybrid), exercise (150 min/week), avoid fructose.

Resmetirom (global) eyed; Indian research on curcumin/vitamin E adjuncts.

Research Gaps, Future Projections, and Calls to Action

Gaps: Community data scarce; pediatric/longitudinal studies needed. Projections: Burden doubles by 2050 sans intervention. MDRF/AIIMS urge policy—screening subsidies, awareness. Social media buzz (40% prevalence tweets) amplifies urgency.

Indian academia leads: MDRF, PGIMER, AIIMS pivotal. Future: Precision medicine via genetics/metabolomics.

Photo by Amit Gaur on Unsplash

Stakeholder Perspectives: From Clinicians to Policymakers

Mohan (MDRF): "Region-specific strategies essential." Duseja (PGIMER): "Diabetes control key." ICMR pushes national registry. Balanced view: Optimism in reversibility, caution on underfunding.